Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors

Although targeted therapies have revolutionized cancer treatment, overcoming acquired resistance remains a major clinical challenge. EZH2 inhibitors (EZH2i), EPZ-6438 and GSK126, are currently in the early stages of clinical evaluation and the first encouraging signs of efficacy have recently emerge...

Descripción completa

Detalles Bibliográficos
Autores principales: Baker, Theresa, Nerle, Sujata, Pritchard, Justin, Zhao, Boyang, Rivera, Victor M., Garner, Andrew, Gonzalvez, Francois
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741719/
https://www.ncbi.nlm.nih.gov/pubmed/26360609

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741719/
https://www.ncbi.nlm.nih.gov/pubmed/26360609

Ejemplares similares